HIGHLIGHTS
- who: Neeltje Steeghs from the The Netherlands Cancer Institute, Amsterdam, The Netherlands have published the article: A phase 1 open-label study to assess the relative bioavailability of TAK-931 tablets in reference to powder-in-capsule in patients with advanced solid tumors, in the Journal: (JOURNAL)
- what: The aim of this phase 1 open-label study, designed based on FDA guidelines , was to characterize the relative bioavailability of TAK931 administered as a prototype tablet in reference to the existing PIC formulation. The relative bioavailability data generated in this study showed that the PKs and . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.